Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126222041 | 12622204 | 1 | I | 20160727 | 20160804 | 20160804 | EXP | TN-MYLANLABS-2016M1031875 | MYLAN | M^RAD A, ESSAFI F, FOUDHAILI N, BLEL Y, THABET H, BRAHMI N, ET AL. ACUTE NIFEDIPINE POISONING: CLINICAL AND PROGNOSIS ASPECTS. ANN-INTENSIVE-CARE 2016;6 (SUPPL. 1): ABSTR. P148. | 0.00 | Y | 0.00000 | 20160804 | OT | TN | TN |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
126222041 | 12622204 | 1 | PS | NIFEDIPINE. | NIFEDIPINE | 1 | Oral | UNK | 90649 | ||||||||||
126222041 | 12622204 | 2 | SS | THEOPHYLLINE | THEOPHYLLINE ANHYDROUS | 1 | Oral | 0 |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
126222041 | 12622204 | 1 | Product used for unknown indication |
126222041 | 12622204 | 2 | Product used for unknown indication |
Outcome of event
Event ID | CASEID | OUTC COD |
---|---|---|
126222041 | 12622204 | DE |
126222041 | 12622204 | OT |
126222041 | 12622204 | HO |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
126222041 | 12622204 | Overdose | |
126222041 | 12622204 | Shock | |
126222041 | 12622204 | Toxicity to various agents |
Reporting Sources (this data is often not reported and may therefore be missing here)
no results found |
Therapies reported
no results found |